Accueil / Tag Archives: Clinical Trials

Tag Archives: Clinical Trials

GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination

Friday, July 21st 2017 at 1:00pm UTC LONDON–(BUSINESS WIRE)– GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced a submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients …

Plus »

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy

Friday, July 21st 2017 at 11:26am UTC Positive opinion based on the results of two randomized Phase 3 trials, TELESTAR and TELECAST PARIS–(BUSINESS WIRE)– Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines …

Plus »

Sage Therapeutics to Report Second Quarter 2017 Financial Results on Thursday, August 3, 2017

Thursday, July 20th 2017 at 8:10pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, August 3, 2017 at 4:30 pm ET …

Plus »

Reviva Pharmaceuticals Announces Addition of a New Member to its Board of Directors

Friday, July 21st 2017 at 9:15pm UTC SANTA CLARA, Calif.–(BUSINESS WIRE)– Reviva Pharmaceuticals, Inc. (Reviva), a privately held, clinical stage pharmaceutical company developing next generation therapies for CNS, cardiopulmonary, and metabolic diseases, today announced that biotech industry veteran Bradley Thompson has joined its Board of Directors. “We are extremely pleased …

Plus »

Ipsen reçoit un avis favorable du CHMP à l’octroi d’une AMM pour Xermelo® (télotristat éthyl), dans le traitement de la diarrhée associée au syndrome carcinoïde chez les patients insuffisamment contrôlés par un analogue de la somatostatine

Friday, July 21st 2017 at 11:26am UTC Avis favorable fondé sur les résultats de deux études randomisées de phase 3, TELESTAR et TELECAST PARIS–(BUSINESS WIRE)– Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd’hui que le Comité des médicaments à usage humain (CHMP : Committee for Medicinal Products for …

Plus »

Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients

Friday, July 21st 2017 at 12:01pm UTC Data Underscore Promise of Syros’ Gene Control Platform to Provide New Approach for Stratifying Patients with Potential to Lead to More Precise Diagnosis and Treatment CAMBRIDGE, Mass.–(BUSINESS WIRE)– Syros Pharmaceuticals (NASDAQ: SYRS) today announced that data providing the foundation of its clinical development …

Plus »

Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease

Thursday, July 20th 2017 at 12:00pm UTC – IW-3718 1500 mg demonstrated a significant reduction in heartburn severity in patients with uncontrolled GERD – – Greater than 50% of patients treated with IW-3718 1500 mg achieved a clinically meaningful reduction in heartburn severity – – IW-3718 1500 mg also showed …

Plus »

Study Demonstrates Paclitaxel Treatment Promotes Breast Cancer Dissemination and Metastasis in a Mena-dependent Manner

Wednesday, July 19th 2017 at 11:55am UTC Mena Knockdown Reverses Paclitaxel-induced Dissemination and Metastasis in MMTV-PyMT-CFP Breast Cancer Transplant Model BOSTON–(BUSINESS WIRE)– MetaStat, Inc. (OTCQB:MTST), a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients, announced today results from a study published online on July 5, 2017 in Science …

Plus »

Regenacy Pharmaceuticals Presents Data Demonstrating that HDAC1,2 Inhibition Improved Cognitive Function in Mouse Models of Alzheimer’s Disease at the Alzheimer’s Association International Conference

Wednesday, July 19th 2017 at 4:30pm UTC — Matthew Jarpe Promoted to Vice President of Research and Development — BOSTON–(BUSINESS WIRE)– Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company that is regenerating biological function by selective protein acetylation, today announced the presentation of preclinical data supporting the use of selective inhibition …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cuZWVpLWJpb3RlY2hmaW5hbmNlcy5jb20vd3AtY29udGVudC91cGxvYWRzLzIwMTUvMDcvU2F0cmEtMi5tcDQiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...